Anti-tumour effects and pharmacokinetic profile of 17-(5′ -isoxazolyl)androsta-4,16-dien-3-one (L-39) in mice: an inhibitor of androgen synthesis
2000
Effects of L-39 on Prostate Cancer in Mice
publication
Evidence: moderate
Author Information
Author(s): Nnane I P, Long B J, Ling Y-Z, Grigoryev D N, Brodie A M
Primary Institution: University of Maryland School of Medicine
Hypothesis
Can L-39 effectively inhibit androgen synthesis and reduce prostate cancer growth in mice?
Conclusion
L-39 significantly reduced tumor growth and PSA levels in mice with prostate cancer.
Supporting Evidence
- L-39 showed potent inhibition of androgen synthesis enzymes.
- L-39 reduced tumor growth and PSA levels significantly in treated mice.
- Pharmacokinetic studies showed rapid absorption and a half-life of 1.51 hours.
Takeaway
L-39 is a new drug that helps stop prostate cancer from growing in mice by blocking hormones that help the cancer grow.
Methodology
L-39 was tested in vitro and in vivo on prostate cancer xenografts in nude mice.
Limitations
Improvements in the bioavailability of L-39 are necessary.
Participant Demographics
Male Balb/c mice were used for the pharmacokinetic studies.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website